Exclusive
scalehealthtech Realize your Healthcare’s Digital Transformation journey with ScaleHealthTech Learn More

Peptris Technologies & Revio Therapeutics Partners for AI-Discovered Drug Candidate

Written by : Dr. Aishwarya Sarthe

March 18, 2025

Category Img

The drug, in the preclinical stage, targets DMD, a rare genetic disorder primarily affecting boys and causing progressive muscle degeneration.

Peptris Technologies, an AI-powered drug discovery startup, has entered into a licensing agreement with US-based Revio Therapeutics to advance the development of its AI-discovered drug candidate, PEPR124 (RT001).

The drug, in the preclinical stage, targets Duchenne Muscular Dystrophy (DMD), a rare genetic disorder primarily affecting boys and causing progressive muscle degeneration.

The terms of the agreement include a licensing deal for PEPR124 (RT001) to Revio Therapeutics for further development in global markets, except in BRICS countries, where Peptris retains commercialization rights.

Strengthening India’s Position in AI-Driven Drug Discovery

Peptris Technologies' breakthrough in AI-powered drug discovery is significant for India’s position in the global biotech landscape. The company’s proprietary platform was instrumental in discovering PEPR124 (RT001), a mutation-agnostic and safe therapeutic candidate that has shown promise in preclinical studies.

This achievement highlights India’s growing contribution to AI-driven drug discovery, with the agreement reflecting global confidence in the potential of AI to address unmet medical needs.

Duchenne Muscular Dystrophy, a genetic disorder with limited treatment options, represents a major unmet need in healthcare.

The global DMD market is valued at over $3 billion, underscoring the significant demand for effective therapies.

As a repurposed therapeutic, PEPR124 (RT001) offers a new avenue of treatment that could change the landscape for patients with DMD, particularly given its demonstrated safety profile and mutation-agnostic nature.


POPULAR CATEGORIES

WEEKLY POPULAR POSTS

ABOUT US

Digital Health News ( DHN) is India’s first dedicated digital health news platform launched by Industry recognized HealthTech Leaders. DHN Is Industry’s Leading Source Of HealthTech Business, Insights, Trends And Policy News.

DHN Provides In-Depth Data Analysis And Covers Most Impactful News As They Happen Across Entire Ecosystem Including Emerging Technology Trends And Innovations, Digital Health Startups, Hospitals, Health Insurance, Govt. Agencies & Policies, Pharmaceuticals And Biotech.

CONTACT US

© Digital Health News 2025